15 Years of Experience with Biphasic Insulin Aspart 30 in Type 2 Diabetes
- PDF / 632,228 Bytes
- 13 Pages / 595.276 x 790.866 pts Page_size
- 3 Downloads / 172 Views
REVIEW ARTICLE
15 Years of Experience with Biphasic Insulin Aspart 30 in Type 2 Diabetes Andreas Liebl1 Sultan Linjawi5
•
Viswanathan Mohan2 • Wenying Yang3 • Krzysztof Strojek4
•
Ó The Author(s) 2018. This article is an open access publication
Abstract Since clinical experience with biphasic insulin aspart 30 (BIAsp 30) in type 2 diabetes mellitus (T2DM) was reviewed in 2012 after 10 years of use worldwide, additional studies have been published that highlight new aspects, including use in real-world populations. Evidence from 35 new studies confirms and builds upon previous work indicating that BIAsp 30 continues to have pharmacodynamic and clinical advantages over biphasic human insulin (BHI 30), including in real-world practice with unselected populations of patients. BIAsp 30 has also been shown to be safe and efficacious as an add-on to dipeptidyl peptidase-4 (DPP-4) inhibitors. Intensification with BIAsp 30 is a safe and effective way to improve glycemic control, and titration performed by patients can achieve results that are at least comparable to those when being guided by healthcare providers. Stepwise intensification using BIAsp 30 is comparable to intensification using a basal–bolus regimen, and twice-daily BIAsp 30 provides similar glycemic control to a basal-plus regimen. Data from large observational studies, in particular, have
& Andreas Liebl [email protected] 1
Department for Internal Medicine, Center for Diabetes and Metabolism, m&i-Fachklinik Bad Heilbrunn, Woernerweg 30, 83670 Bad Heilbrunn, Germany
2
Dr. Mohan’s Diabetes Specialties Centre and Madras Diabetes Research Foundation, Chennai, India
3
China-Japan Friendship Hospital, Beijing, China
4
Department of Internal Diseases Diabetology and Cardiometabolic Diseases, SMDZ in Zabrze, Medical University of Silesia, Katowice, Poland
5
Coffs Endocrine and Diabetes Services, Coffs Harbour, NSW 2450, Australia
identified patient-related characteristics that are associated with improved clinical responses, suggesting that earlier initiation and intensification of therapy is warranted. Finally, new health-economic analyses continue to confirm that BIAsp 30 is cost effective versus other therapies such as BHI 30, neutral protamine Hagedorn (NPH), or insulin glargine in both insulin-naı¨ve and insulin-experienced patients. After 15 years of clinical use worldwide, analysis of more recent 5-year data indicates that BIAsp 30 remains a safe, effective, and simple-to-use insulin for initiation and intensification by diabetes specialists and primary care physicians in a variety of patients with T2DM.
Key Points Evidence from new studies including unselected populations of patients with type 2 diabetes mellitus (T2DM) confirms that BIAsp 30 has advantages over regular human insulin. Patients with T2DM can safely and effectively titrate BIAsp 30 to improve glycemic control. BIAsp 30 is cost effective versus other insulin therapies in both insulin-naı¨ve and insulinexperienced patients.
A. Liebl et al.
We searched
Data Loading...
